Terms: = Prostate cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Diagnosis
29 results:
1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
2. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive prostate cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract] [Full Text] [Related]
3. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM
World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236
[TBL] [Abstract] [Full Text] [Related]
4. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
[TBL] [Abstract] [Full Text] [Related]
5. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
[TBL] [Abstract] [Full Text] [Related]
6. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract] [Full Text] [Related]
7. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract] [Full Text] [Related]
8. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population.
Kagawa M; Kawakami S; Yamamoto A; Suzuki O; Eguchi H; Okazaki Y; Akagi K; Tamaru JI; Arai T; Yamaguchi T; Ishida H
Jpn J Clin Oncol; 2021 Apr; 51(4):639-645. PubMed ID: 33244609
[TBL] [Abstract] [Full Text] [Related]
9. Report of a germline double heterozygote in msh2 and PALB2.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Patsea E; Lypas G; Nasioulas G
Mol Genet Genomic Med; 2020 Oct; 8(10):e1242. PubMed ID: 32853479
[TBL] [Abstract] [Full Text] [Related]
10. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract] [Full Text] [Related]
11. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Features and Therapeutic Outcomes in Men with Advanced prostate cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract] [Full Text] [Related]
13. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract] [Full Text] [Related]
14. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous prostate cancer with Intact MMR: diagnosis and Analysis of the Family Pedigree.
Liu W; Zhang D; Tan SA; Liu X; Lai J
Anticancer Res; 2018 Aug; 38(8):4847-4852. PubMed ID: 30061258
[TBL] [Abstract] [Full Text] [Related]
15. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
[TBL] [Abstract] [Full Text] [Related]
16. Tumor development in Japanese patients with Lynch syndrome.
Saita C; Yamaguchi T; Horiguchi SI; Yamada R; Takao M; Iijima T; Wakaume R; Aruga T; Tabata T; Koizumi K
PLoS One; 2018; 13(4):e0195572. PubMed ID: 29672549
[TBL] [Abstract] [Full Text] [Related]
17. Sebaceous tumours: more than skin deep.
Jockenhöfer F; Schimming TT; Schaller J; Moege J; Livingstone E; Salva KA; Zimmer L; Schadendorf D; Rösch A
Gut; 2018 Nov; 67(11):1957. PubMed ID: 29247065
[TBL] [Abstract] [Full Text] [Related]
18. prostate cancer Screening in a New Era of Genetics.
Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
[TBL] [Abstract] [Full Text] [Related]
19. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
[TBL] [Abstract] [Full Text] [Related]
20. A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
Kerr L; Rewhorn MJ; Longmuir M; Fraser S; Walsh S; Andrew N; Leung HY
BMC Cancer; 2016 Jul; 16():529. PubMed ID: 27456091
[TBL] [Abstract] [Full Text] [Related]
[Next]
